Why Is Fluorouracil So Hard to Find? [Explained for 2026]

If you or a loved one relies on fluorouracil — whether as an IV chemotherapy infusion or a topical cream — and you've run into trouble getting it filled recently, you're not alone. Fluorouracil, also known as 5-FU or by its brand name Adrucil (injection) and Efudex (cream), has experienced ongoing supply disruptions that have left patients and oncology clinics scrambling since as early as 2023.

In this guide, we'll explain exactly why fluorouracil is hard to find, which manufacturers are experiencing shortages, what the current status is as of 2026, and what you can do if your pharmacy or cancer center can't get it.

Is Fluorouracil Currently in Shortage?

Yes. As of early 2026, fluorouracil injection remains on the ASHP (American Society of Health-System Pharmacists) drug shortage list. Several manufacturers have reported manufacturing delays and supply interruptions, while others still have product available. Here is the current manufacturer breakdown:

Accord: On shortage due to manufacturing delays. 100 mL vials back-ordered.

Alembic: On shortage; reason not publicly disclosed.

Eugia US: On shortage; reason not disclosed.

Fresenius Kabi: Available — 10 mL, 20 mL, and 100 mL vials.

Sagent: Available.

So while fluorouracil is not completely unavailable nationwide, hospital pharmacies and outpatient infusion centers may not be receiving it from their regular suppliers, leading to real treatment delays for cancer patients.

Why Is Fluorouracil Hard to Find? The Root Causes

Fluorouracil has been in use since its initial FDA approval in 1962 — over 60 years. It's one of the oldest and most widely used chemotherapy agents in the world, forming the backbone of common regimens like FOLFOX and FOLFIRI for colorectal cancer. Given its age and generic status, its price is low, which creates thin profit margins for manufacturers. This economic reality is at the heart of why shortages happen:

Low manufacturing margins: With generic fluorouracil priced at just a few dollars per vial, manufacturers have little financial incentive to maintain large safety stocks.

Manufacturing quality issues: Sterile injectable drugs are complex to manufacture. GMP (Good Manufacturing Practice) issues can cause temporary shutdowns.

High demand: Colorectal cancer rates remain high. Fluorouracil is a first-line agent in multiple protocols, so demand is consistently large.

Concentrated supply chain: A handful of manufacturers supply most of the US market. When even one goes offline, the ripple effect is immediate.

Who Is Most Affected by the Fluorouracil Shortage?

The fluorouracil shortage affects several groups of patients and healthcare settings:

Cancer patients on active chemotherapy: Those on FOLFOX, FOLFIRI, or FLOT regimens depend on fluorouracil every two weeks. A supply gap can delay critical treatment cycles.

Outpatient infusion centers: Smaller clinics that don't have large purchasing power may run out before their supplier restocks.

Dermatology patients: Those using topical fluorouracil cream (Efudex, Carac) for actinic keratosis or superficial basal cell carcinoma may face pharmacy-level shortages.

What Is the Difference Between the IV Shortage and the Topical Cream Shortage?

These are two distinct supply chains. The FDA shortage list specifically refers to fluorouracil injection (50 mg/mL vials used in chemotherapy). Topical fluorouracil creams — sold as Efudex, Carac, Tolak, and in generic form — are manufactured separately and face their own intermittent availability issues. For example, Carac (0.5% cream) has experienced ongoing supply challenges as of 2026, even when not formally listed on the FDA shortage database.

The situation differs by form, manufacturer, and region. Some pharmacies have topical fluorouracil in stock while others have been waiting weeks for a new shipment.

What Can You Do If Your Pharmacy Is Out of Fluorouracil?

Here are concrete steps to take if you're facing a shortage:

Ask your pharmacy to check with alternate distributors. Pharmacies can often source from secondary wholesalers when their primary supplier is out.

Call multiple pharmacies in your area. Availability varies significantly pharmacy to pharmacy, even within the same zip code.

Use medfinder.

Rather than spending hours on hold, medfinder calls pharmacies on your behalf to find which ones have your medication in stock, and texts you the results.

Talk to your oncologist or dermatologist. Your provider can sometimes help locate alternative suppliers, or discuss whether switching to capecitabine (an oral prodrug of 5-FU) is appropriate for your situation.

Check hospital pharmacies. Larger hospital or academic medical center pharmacies often maintain larger inventory buffers and may have stock when retail pharmacies don't.

How Long Has Fluorouracil Been in Shortage?

The fluorouracil injection shortage was first created on the ASHP Drug Shortage Database in January 2023. While severity has varied over time, the shortage has remained active through early 2026. This multi-year duration reflects the structural supply chain challenges with older generic injectable chemotherapy drugs — not a one-time manufacturing hiccup.

Will Fluorouracil Come Back in Full Supply?

The FDA and ASHP continue to work with manufacturers to resolve the shortage. With Fresenius Kabi and Sagent still producing available product, a complete national stockout is unlikely. However, regional shortages and delays will continue until all manufacturers restore full production capacity.

For the most current shortage updates, see our Fluorouracil shortage update for patients. If you need help locating a pharmacy with your medication in stock, medfinder can help.